Strategic Advisors LLC lessened its position in Amgen, Inc. (NASDAQ:AMGN) by 19.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,111 shares of the medical research company’s stock after selling 729 shares during the quarter. Strategic Advisors LLC’s holdings in Amgen were worth $541,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in AMGN. Baker Ellis Asset Management LLC bought a new position in Amgen in the third quarter valued at approximately $108,000. Jackson Grant Investment Advisers Inc. grew its stake in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares in the last quarter. Phocas Financial Corp. bought a new position in Amgen in the second quarter valued at approximately $110,000. Omnia Family Wealth LLC grew its stake in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Salem Investment Counselors Inc. grew its stake in Amgen by 4.7% in the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 36 shares in the last quarter. 78.03% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on AMGN shares. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a research note on Friday, October 27th. Citigroup downgraded Amgen to a “neutral” rating in a research note on Monday, December 18th. Royal Bank of Canada reduced their target price on Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research note on Thursday, October 26th. Goldman Sachs Group downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Argus upgraded Amgen from a “hold” rating to a “buy” rating and lifted their target price for the stock from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Amgen currently has an average rating of “Hold” and an average price target of $191.84.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Tuesday. The stock has a market capitalization of $132,259.19, a price-to-earnings ratio of 71.42, a P/E/G ratio of 2.19 and a beta of 1.42. Amgen, Inc. has a one year low of $152.16 and a one year high of $201.23. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $2.89 earnings per share. equities analysts predict that Amgen, Inc. will post 13.21 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a yield of 2.88%. Amgen’s payout ratio is 205.45%.
Amgen declared that its Board of Directors has authorized a stock buyback plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 4,575 shares of company stock valued at $818,361 over the last 90 days. 0.19% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/20/strategic-advisors-llc-sells-729-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.